BC Renal's Dr. Adeera Levin discusses how patients with chronic kidney disease (CKD) and Type 2 diabetes may benefit from treatment with SGLT2 inhibitors. Notably, existing treatments with RAAS inhibition provide limited cardiovascular benefits to patients. Since 2015, there have been a number of clinical trials exploring SGLT2 inhibitors, looking at heart failure, cardiovascular, and kidney outcomes. Evidence shows that SGLT2 inhibitors can provide improved outcomes for patients, including slowing the progression of kidney disease (as measured by eGFR decline) and can reduce mortality in kidney patients. In general, the risk of adverse effects (AEs) is low for this class of drug. Dr. Levin highlights the key findings from these clinical trials, including how SGLT2 inhibitors can be useful for addressing blood pressure control, ischemia, obesity, hyperglycemia, inflammation and several other indicators. Lastly, she talks about cost effectiveness and coverage of SGLT2 inhibitors.

#ChronicKidneyDisease #Diabetes #ClinicalTrials #Drugs #KidneyCare